ArticleHuman cell2026
Construction of a risk model based on exosome-related genes predict clinical prognosis and therapeutic response and revealing TIMP1 as a promising target in colorectal cancer.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Various exosome-derived proteins have been reported to play essential roles in regulating colorectal cancer progression and affecting the prognosis of cancer patients. It is necessary to explore the critical exosome-related genes in colorectal cancer. In this study, 23 differentially expressed exosome-related genes associated with prognosis in colorectal cancer (CRC) were identified based on two datasets, The Cancer Genome Atlas (TCGA) and exoRbase. Based on machine learning-Boruta and lasso-Cox regression-nine essential genes were finally identified, and a risk model was constructed. The risk model was able to predict the prognosis of the patients well. Specifically, the prognosis of high-risk patients was worse, and the prognosis of low-risk patients was better. Multivariate Cox regression revealed that the risk model was an independent prognostic factor. Mechanism studies showed that pathways such as MYOGENESIS, APICAL JUNCTION, Epithelial-Mesenchymal Transition (EMT), ANGIOGENESIS, and KRAS SIGNALING DN were highly enriched in the high-risk group. In addition, tumor-promoting immune cells, such as Treg cells and macrophages, exhibited increased activity in the high-risk group, suggesting that high-risk patients may be less responsive to immunotherapy. Furthermore, in multiple external immunotherapeutic and chemotherapeutic datasets, we found that high-risk patients are less sensitive to therapy than low-risk patients, suggesting that this risk score may predict immune and chemotherapy response. Scoring the importance of nine genes, we found that TIMP1 was the most critical exosome-related gene in colorectal cancer patients. Knockdown of TIMP1 in colorectal cancer cells significantly inhibited the proliferation and migration of colorectal cancer cells. In conclusion, we identified several crucial colorectal cancer exosome-associated genes using public datasets and machine learning, and constructed risk models to predict prognosis and response to immunotherapy. TIMP1 was further identified as a critical oncogene in patients with colorectal cancer. Our results provide a theoretical basis for subsequent exosome-based preclinical trials.
Indexed as
Identifiers
41612047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.